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Human dihydroorotate dehydrogenase (HsDHODH) is a key enzyme of pyrimidine
de novo biosynthesis pathway. It is located on the mitochondrial inner membrane and
contributes to the respiratory chain by shuttling electrons to the ubiquinone pool. We
have discovered ascofuranone (1), a natural compound produced by Acremonium
sclerotigenum, and its derivatives are a potent class of HsDHODH inhibitors. We
conducted a structure–activity relationship study and have identified functional groups
of 1 that are essential for the inhibition of HsDHODH enzymatic activity. Furthermore,
the binding mode of 1 and its derivatives to HsDHODH was demonstrated by co-
crystallographic analysis and we show that these inhibitors bind at the ubiquinone
binding site. In addition, the cytotoxicities of 1 and its potent derivatives 7, 8, and 9
were studied using human cultured cancer cells. Interestingly, they showed selective
and strong cytotoxicity to cancer cells cultured under microenvironment (hypoxia and
nutrient-deprived) conditions. The selectivity ratio of 8 under this microenvironment
show the most potent inhibition which was over 1000-fold higher compared to that
under normal culture condition. Our studies suggest that under microenvironment
conditions, cancer cells heavily depend on the pyrimidine de novo biosynthesis pathway.
We also provide the first evidence that 1 and its derivatives are potential lead candidates
for drug development which target the HsDHODH of cancer cells living under a tumor
microenvironment.
Keywords: pyrimidine de novo biosynthesis, ubiquinone binding-site inhibitor, tumor bioenergetics, tumor
microenvironment, structure–activity relationship, anticancer activity, ascofuranone, crystal structure
Frontiers in Pharmacology | www.frontiersin.org 1 September 2018 | Volume 9 | Article 997
fphar-09-00997 September 1, 2018 Time: 10:24 # 2
Miyazaki et al. Ascofuranone Targets HsDHODH Under Tumor-Microenvironment
INTRODUCTION
Mitochondria play important roles in energy metabolism
by eukaryotic cells. The mammalian mitochondrial electron
transport chain consists of four enzyme complexes located
in the mitochondrial inner membrane: complexes I, II, III,
and IV. Complexes I and II transfer reducing equivalents
from NADH and succinate, respectively, to complex III via
the ubiquinone pool, and complex III further transfers these
equivalents to complex IV via cytochrome c. Electrons from
complex IV are finally transferred to dioxygen, resulting in the
production of water. ATP synthase produces ATPs by oxidative
phosphorylation utilizing the transmembrane electrochemical
gradient maintained by proton pumping activities of complexes
I, III, and IV (Alberts, 2014). In addition to energy metabolism,
mitochondria are also important organelle for pyrimidine de novo
biosynthesis. In mammals, under physiological condition,
pyrimidines are synthesized through both de novo biosynthesis
and salvage pathways (Berg et al., 2015). Among the six
enzymes from the de novo biosynthesis pathway, dihydroorotate
dehydrogenase (DHODH), the fourth enzyme and rate-limiting
step, catalyzes the electron transfer from dihydroorotate to
the flavin mononucleotide (FMN) and from reduced FMN to
an acceptor. Depending on its localization, DHODH can be
classified as family 1 and 2. Family 1 DHODHs are cytosolic
enzymes and further sub-classified as family 1A and 1B according
to the ability to use fumarate (Inaoka et al., 2008; Kubota
et al., 2018) or NAD+ (Jensen and Bjornberg, 1998) as electron
acceptor, respectively. DHODHs from trypanosomatid parasites
belong to family 1A and have been suggested to be drug targets
to combat Chagas disease (Inaoka et al., 2016, 2017), African
trypanosomiasis (Arakaki et al., 2008; Kubota et al., 2018),
and leishmaniasis (Pinheiro et al., 2013). Family 2 DHODHs
are membrane-bound enzymes and use quinone pool as its
acceptor (Rawls et al., 2000) and thus, contribute to the formation
of the electrochemical gradient through complexes III and
IV activities (Löﬄer et al., 1997; Rawls et al., 2000). Hence,
family 2 DHODH is the key enzyme linking pyrimidine de
novo biosynthesis pathway and the respiratory chain. Indeed,
it has been reported that inhibition of complex III impairs
the efficiency of pyrimidine de novo biosynthesis (Khutornenko
et al., 2010). Family 2 DHODHs are conserved in several
pathogens such as Helicobacter pylori (Copeland et al., 2000;
Ohishi et al., 2018), those causing fungal infections (Oliver
et al., 2016; Wiederhold, 2017), Toxoplasma gondii (Hortua
Triana et al., 2016), and Plasmodium falciparum (Singh et al.,
2017). The ubiquinone binding site in P. falciparum DHODH
(PfDHODH) is known to be significantly divergent from its
human counterpart and several groups have reported on the
discovery of parasite-specific DHODH inhibitors (Booker et al.,
2010; Wadood and Ulhaq, 2013; Xu et al., 2013; Kokkonda et al.,
2016; Vyas et al., 2016; Azeredo et al., 2017; Maetani et al., 2017).
Recently, Phase Ia/Ib studies of a potent and specific PfDHODH
inhibitor, DSM265, have been published with promising results
(McCarthy et al., 2017; Sulyok et al., 2017). Intervenolin, a natural
product isolated from Nocardia sp. ML96-86F2 (Kawada et al.,
2013), and its derivatives were found to be potent inhibitors
of H. pylori DHODH and proved to have greater efficacy for
treatment of H. pylori infection compared to the conventional
triple therapy (i.e., omeprazole, amoxicillin, and clarithromycin)
(Ohishi et al., 2018). In human, it is known that pyrimidine de
novo biosynthesis is upregulated in cancer and activated immune
cells as well as virus-infected cells in order to meet the high
demand for pyrimidines due to enhanced cell/virus proliferation
compared to normal/uninfected cells (Ahmed, 1984; Weber et al.,
1987; Okesli et al., 2017). Leflunomide, a human DHODH
(HsDHODH) inhibitor currently used for the treatment of
rheumatoid arthritis (RA), has been reported to have an anti-
cancer and anti-viral activity (Teschner and Burst, 2010; Vyas
and Ghate, 2011; Lolli et al., 2018). Leflunomide is a prodrug
that is metabolized to teriflunomide (or A771726) and has a
long half-life in blood, a property, however, which becomes a
disadvantage once secondary infection appears. The high cost
required for treatment of RA by leflunomide (Benucci et al., 2011)
in addition to other disease-modifying antirheumatic drugs (i.e.,
cyclosporine A, sulfasalazine, leflunomide, and methotrexate)
suggests that alternative HsDHODH inhibitors with lower
treatment costs which are easier to administer are desired.
Ascofuranone (AF or compound 1), a prenylphenolic
compound produced by filamentous fungi, Acremonium
sclerotigenum (Hijikawa et al., 2016), was reported to strongly
inhibit the ubiquinol oxidase activity of Trypanosoma brucei
mitochondrial alternative oxidase (TAO) (Minagawa et al., 1996;
Kido et al., 2010), an enzyme essential for parasite survival
which is absent in mammals (Shiba et al., 2013). Besides its
anti-trypanosomal activity, 1 and its derivatives are known to
have anti-cancer (Magae et al., 1986) and anti-viral activity
(Tamura et al., 1968) in mammals. The target of 1 in mammals
has previously been unidentified, but recent reports indicate
that 1 is an HsDHODH inhibitor (Kita et al., 2012; Shen
et al., 2016). It has been reported that several inhibitors of
mitochondrial respiratory chain complexes such as rotenone
(Complex I) and atpenin A5 (Complex II) exhibit specific
cytotoxicity on pancreatic cancer cells only under tumor
microenvironment mimicking conditions (such as hypoxia and
nutrient-deprived culture) (Momose et al., 2010). Considering
that DHODH is an important enzyme required for pyrimidine
de novo biosynthesis and shuttles reducing equivalents to
the mitochondrial respiratory chain, we have previously
hypothesized that HsDHODH inhibitor may also show specific
cytotoxicity to mammalian cells under microenvironment
conditions, particularly when dioxygen and the substrate for
pyrimidine salvage pathway are limiting (Tomitsuka et al., 2009;
Sakai et al., 2012).
In this study, we have determined the inhibition mechanism of
1 and its functional groups essential for HsDHODH inhibition,
through a comprehensive structure–activity relationship (SAR)
study including co-crystal structures of HsDHODH with 1 and
its derivatives. Furthermore, we have examined the anti-cancer
effects of 1 on a panel of 39 types of human cancer cells. We show
that 1 and its derivatives have little effect on the growth of DLD-
1 cancer cells under normal culture conditions; however, under
hypoxia and nutrient-deprived conditions, the survival rate of
these cancer cells is drastically decreased. Our studies indicate
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that HsDHODH is a potential drug target and that 1 is a lead
compound to develop new therapeutic agent targeting tumors
living under microenvironment condition.
MATERIALS AND METHODS
Protein Purification, Crystallization, and
Enzyme Activity
Recombinant human DHODH was purified, crystallized,
and assayed as previously described (Inaoka et al., 2016)
without modification. Bovine mitochondrial fractions were
prepared as previously described (Kita et al., 1988) and
NADH dehydrogenase (complex I), succinate:quinone
reductase (complex II), quinol oxidase (complexes III–IV),
NADH-cytochrome c reductase (complexes I–III), and succinate-
cytochrome c (complexes II–III) activities were assayed following
an established method (Takamiya et al., 1986; Miyadera et al.,
2001; Matsumoto et al., 2008; Kido et al., 2010; Nihashi et al.,
2017).
Synthesis of 1 and Its Derivatives
1 and all of its derivatives (compounds 2–23, see Tables 1–3) were
synthesized essentially as previously described (Kita et al., 2012;
Saimoto et al., 2012, 2015).
Data Collection and Structure
Determination
X-ray diffraction data of HsDHODH-1 complex were collected
at 100 K on the beamline BL41XU (λ = 1.00000 Å; Rayonix
MX225HE CCD detector) at SPring-8 (Harima, Japan). X-ray
diffraction data of compounds 6, 7, 8, 9, and 12 complex crystals
were collected at 100 K on the beamline BL-17A (λ = 0.98000 Å;
ADSC Quantum 315r) at Photon Factory (Tsukuba, Japan). For
X-ray diffraction experiments at 100 K, a crystal mounted on a
nylon loop was transferred to reservoir solution supplemented
with 20% (w/v) glycerol and was then flash-frozen in liquid
nitrogen stream. All data sets were processed and scaled using
HKL-2000 (Otwinowski and Minor, 1997). The structure of the
HsDHODH-9 complex was solved by molecular replacement
using the refined protein coordinates of HsDHODH-mii-4-087
complex (PDB code 3W7R) (Inaoka et al., 2016) as a search
model. All other structures of HsDHODH inhibitor complexes
were solved by molecular replacement using the refined protein
coordinates of HsDHODH-9 complex (PDB code 5ZF4) as
a search model. MOLREP program (Vagin and Teplyakov,
1997) as implemented within CCP4 (Winn et al., 2011)1 was
used for molecular replacement. Structural adjustments were
made by iterative cycles of manual adjustments in COOT
(Emsley and Cowtan, 2004) and refinements by REFMAC5
(Murshudov et al., 1997). Statistics of X-ray data collection
and refinement are summarized in Supplementary Table S1.
Graphical representations were generated with PyMOL2.
1http://www.ccp4.ac.uk/
2http://www.pymol.org
TABLE 1 | Inhibition of human dihydroorotate dehydrogenase (DHODH) by
furanone ring substituted ascofuranone (1) derivatives.
Compound R IC50 (nM)
Ascofuranone (1) 37.5 ± 12
Rac-AF (2) 97.4 ± 7.3
CCB (3) 74.1 ± 22
4 98.0 ± 5.5
5 32.9 ± 2.7
6 63.9 ± 11
7 6.4 ± 0.2
8 6.0 ± 0.5
9 4.2 ± 0.4
The IC50 of reference compounds brequinar and A771726 was 4.6 ± 0.5 and
773 ± 78 nM, respectively, in our assay condition described in the section
“Materials and Methods.” Oxygen and chlorine atoms were colored in red and
green, respectively, to facilitate the visualization of compounds in other figures
generated by Pymol.
39-Cancer Cell Panel Assay
The growth inhibition activity of compounds 1, 6, 7, 8, 9, and
12 against 39 types of human cancer cell lines was evaluated
as previously reported (Yamori, 2003). This panel of human
cancer cell lines consists of the following 39 human cancer
cell lines: lung cancer, NCI-H23, NCI-H226, NCI-H522, NCI-
H460, A549, DMS273, and DMS114; colorectal cancer, HCC-
2998, KM-12, HT-29, HCT-15, and HCT-116; gastric cancer,
MKN-1, MKN-7, MKN-28, MKN-45, MKN-74, and St-4; ovarian
cancer, OVCAR-3, OVCAR-4, OVCAR-5, OVCAR-8, and SK-
OV-3; breast cancer, BSY-1, HBC-4, HBC-5, MDA-MB-231,
and MCF-7; renal cancer, RXF-631L and ACHN; melanoma,
LOX-IMVI; glioma, U251, SF-295, SF-539, SF-268, SNB-75,
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TABLE 2 | Inhibition of human DHODH by 1 derivatives with different linker
structures.
Compound R IC50 (nM)
Ascochlorin (10) >1,000 (33%)
11 67.2 ± 2.8
12 21.5 ± 0.3
13 349 ± 96
14 >1,000 (35%)
15 123 ± 18
16 >1,000 (21%)
17 71.4 ± 2.4
18 >1,000 (37%)
Value in parenthesis represents the average inhibition (%) at 1,000 nM
concentration of the derivatives. Oxygen and chlorine atoms were colored in red
and green, respectively, to facilitate the visualization of compounds in other figures
generated by Pymol.
and SNB-78; and prostate cancer, DU-145 and PC-3. All the
above cancer cell lines from the panel were cultured in RPMI
1640 medium with 5% (v/v) fetal bovine serum, 100 units/ml
penicillin, and 100 µg/ml streptomycin at 37◦C under 5% CO2
atmosphere.
Cell Culture
Human colorectal adenocarcinoma cells (DLD-1; Taiho
Pharmaceutical Company, Japan) were grown in RPMI-1640
(Gibco), and human dermal fibroblast cells (HDF; Zenbio, Inc.,
United States) were grown in DMEM/F12 (Gibco), containing
TABLE 3 | Inhibition of human DHODH by 1 derivatives with different substitutions
on benzene group.
Compound Structure IC50 (nM)
19 >1,000 (3%)
20 3,530 ± 0.51
21 >1,000 (3%)
Colletorin B (22) >1,000 (20%)
24 >1,000 (36%)
Value in parenthesis represents the average inhibition (%) at 1,000 nM
concentration of the derivatives. Oxygen and chlorine atoms were colored in red
and green, respectively, to facilitate the visualization of compounds in other figures
generated by Pymol.
10% heat-inactivated fetal bovine serum (FBS, Gibco) at 37◦C
under 5% CO2. For normal cell culture condition, cells were
maintained under 5% CO2 and 21% oxygen. For hypoxia and
nutrient-deprived culture conditions, cells were incubated under
1% oxygen in glucose and glutamine-free DMEM (Gibco)
without FBS.
Cytotoxicity Assay
DLD-1 or HDF cells were seeded at 2.5 × 104 cells/well on a 96-
well plate with normal medium, and cultured overnight under
normal culture condition. The cells were washed with PBS and
the medium was replaced to either normal medium or glucose
and glutamine-free DMEM without FBS. Test compounds or
DMSO as a control were added to the wells. The cells in normal
medium were cultured under normal culture conditions, while
cells in nutrient-deprived medium were cultured under hypoxia
condition. After 24 or 48 h incubation, the cells were washed
with PBS, 100 µl of fresh normal medium, and 10 µl of Cell
Counting Kit-8 solution (Donjindo, Japan) was added to each
well. After 3 h incubation under normal culture condition, the
absorbance was measured at 450 nm using SpectraMax M2e-TUY
microplate reader (Molecular Devices). Cell viability of test wells
was calculated based on absorbance of control wells containing
DMSO according to manufacturer’s protocol.
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FIGURE 1 | Structure of ascofuranone (AF or 1). The benzene, linker and
terminal groups are indicated. Oxygen and chlorine atoms were colored in red
and green, respectively, to facilitate the visualization of compounds in other
figures generated by Pymol.
RESULTS
Structure–Activity Relationship of 1
Against HsDHODH
We have previously designed and synthesized several 1
derivatives targeting TAO for anti-trypanosomal drug
development (Saimoto et al., 2012; Shiba et al., 2013). After
evaluation of over 100 derivatives of 1 against HsDHODH
activity, a comprehensive SAR study was conducted. As shown
in Figure 1, the structure of 1 can be divided into benzene,
linker and terminal groups. Initially, several 1 derivatives
possessing changes in the terminal group were evaluated
(Table 1). Under our assay condition, the reference compounds
brequinar and A771726 inhibited HsDHODH with IC50 of 4.6
and 773 nM, respectively, while 1 inhibited HsDHODH with
an IC50 of 37.5 nM (Table 1). When racemic-AF (2) was tested,
the IC50 increased to 97.4 nM, indicating that the S-isomer
(1) is preferable for inhibition of HsDHODH. The terminal
group from 1 (furanone ring) was shown to be dispensable for
HsDHODH inhibition, as indicated by the IC50 of colletochlorin
B (3) (74.1 nM). Consistent with this notion, several groups
replacing the furanone ring from 1, such as 4, 5, and 6, have
little effect on the IC50s as shown in Table 1. However, changing
the furanone ring to other groups such as in 7, 8, and 9,
showed a sharp decrease in the IC50s to 6.4, 6.0, and 4.2 nM,
respectively. This indicates that, although the furanone ring
is not required for HsDHODH inhibition, its terminal group
should be explored in an attempt to obtain derivatives with
higher potency than 1. Secondly, modifications at the linker
group were also evaluated (Table 2). Ascochlorin (10), another
metabolite isolated from A. sclerotigenum which has a shorter
linker length than 1, has previously been reported to potently
inhibit complex III by binding at both Qo and Qi sites (Berry
et al., 2010). However, 10 was not an effective HsDHODH
inhibitor and even at 1,000 nM it only inhibited HsDHODH
activity by 33% (Table 2). A comparison of 4 and 11 indicates
that a change in the methyl group position from the second
isoprene unit does not affect their inhibition potency (IC50
of 98.0 nM versus 67.2 nM, respectively). However, when the
terminal pivaloyl group from 11 was changed to an isopropyl
group 12 (IC50 of 21.5 nM), there was about threefold increase in
inhibition potency. Compared to 4, where the methyl group from
the first isoprene unit was removed (see 13), the IC50 increased to
349 nM (about 3.5-fold decrease), indicating that this group may
play a significant role in the binding of the inhibitor (Table 2).
Of particular interest was the finding, as shown by compound
14, that when all of the double bonds from the linker group are
removed, inhibition activity is abolished. Hence, it was important
to evaluate the individual contribution of the double bonds
in linker group (Table 2). It became evident that the double
bond at the first isoprene unit is the one critical for HsDHODH
inhibition (Table 2), as shown by the change in the IC50s of 15
(123 nM)/16 (>1,000 nM) and 17 (71.4 nM)/18 (>1,000 nM)
pair compounds. Finally, the essential groups from benzene
group were evaluated (Table 3). When the 1-aldehyde group
from 2 was changed to a ketone group 19, the inhibition activity
was lost. Similarly, reduction of 1-aldehyde to hydroxyl group
in 20 increased the IC50 to 3,530 nM. Next, the contribution
of 4-O− group was evaluated. Comparison of 1 and 21 makes
it clear that the 4-O− group is indeed essential for inhibition.
Removal of 5-chlorine in 22 as well as the 6-methyl in 23 also
showed >13-fold increase in the IC50s in comparison to 3. As
indicated in Table 3, any substitution at positions 1, 4, 5, and
6 in the benzene ring (Figure 1) have a negative impact on
HsDHODH inhibition activities. The contribution of 2-OH
group to inhibition of HsDHODH could not be assessed in this
study due to difficulties in the synthesis of 1 derivatives with
substitutions only at this position in the benzene ring.
Structural Insights Into the HsDHODH
Inhibition Mechanism by 1 and Its
Derivatives
The binding mode of 1 and its derivatives was investigated
by co-crystallographic analysis and through the generation of
structures of HsDHODH in complex with 1, 6, 7, 8, 9, and 12
(Supplementary Figures S1–S6, respectively). In all co-crystal
structures, the inhibitors were bound at a hydrophobic cavity
formed by N-terminal residues, which is believed to be the
ubiquinone binding site (Figures 2A,B). All the substituents from
the benzene group, that were found to be essential for inhibition
of HsDHODH activity by the SAR analysis, interacted tightly with
surrounding amino acid residues (Figure 2C). The 1-aldehyde
group was found to interact with His56, Phe98, and Tyr356
through hydrophobic interaction ranging from 3.18 to 3.49 Å
(Figure 2C). The 4-OH group, which was previously shown to
be deprotonated (4-O−) at physiological pH (Berry et al., 2010),
was within hydrogen bond distance to εN2 from Gln47 and
εN/ηN2 from Arg136 (Figure 2C). The 5-chlorine and 6-methyl
groups interact with εN from Arg136 through halogen bond and
γC from Val134 through hydrophobic interactions, respectively
(Figure 2C). An additional interaction between benzene 2-OH
group and main chain carbonyl group from Leu359 which
was mediated by a water molecule (Supplementary Figure S5)
Frontiers in Pharmacology | www.frontiersin.org 5 September 2018 | Volume 9 | Article 997
fphar-09-00997 September 1, 2018 Time: 10:24 # 6
Miyazaki et al. Ascofuranone Targets HsDHODH Under Tumor-Microenvironment
FIGURE 2 | Representative crystal structure of HsDHODH in complex with 1
and its derivatives. (A) Overall structure of HsDHODH in complex with 9.
Cartoon model is colored in rainbow from blue (N terminus) to red (C
terminus). FMN and orotate (ORO) molecules are shown in yellow ball and
stick models. Compound 9 is shown in white ball and stick model. (B) Surface
presentation of HsDHODH in complex with 9 view from the same angle as (A).
Colors are according to the following hydrophobicity scale: red, high
hydrophobicity and white, low hydrophobicity
(www.pymolwiki.org/index.php/Color_h). (C) Inhibitor binding site of
HsDHODH. FMN and orotate (ORO) molecules are shown in gray ball and
stick models. Compound 9 is shown in white ball and stick model. The black
dashed lines represent hydrogen bonds. The yellow dashed lines represent
important hydrophobic interactions. The red dashed line represents halogen
bond. Water molecules, which interact with both 9 and HsDHODH through
hydrogen bonds, are shown as red sphere.
was only observed in compound 9. This is a specific feature
that could explain why compound 9 shows the most potent
inhibition of HsDHODH activity. The double bond from the
first isoprene unit, which was shown to be essential by the
SAR analysis (Table 2), was found to interact with βC from
Ala55 via CH—pi bond (Figure 2C). Also, the methyl group
can be seen to interact hydrophobically with βC from Leu46
(Figure 2C). The interaction of terminal group varied according
to each inhibitor. For all compounds co-crystallized with
HsDHODH in this study, the interaction of the terminal group
and Met43, Thr63, and Pro364 were observed (Supplementary
Figures S1–S6). Additional interaction is as follows: compounds
1 (Supplementary Figure S1), 7 (Supplementary Figure S3),
and 12 (Supplementary Figure S6) with Leu359 through
hydrophobic interactions; 6 showed an intermolecular hydrogen
bond between terminal OH and benzene 2-OH bridged by a water
molecule (Supplementary Figure S2); 8 with Leu359 and Met111
(Supplementary Figure S4); and 9 with Tyr38 (through a water
molecule), Thr63, Leu67, Met111, and L359 (Supplementary
Figure S5).
Anti-proliferative Effect of 1 and Its
Derivatives
Since HsDHODH is an anti-cancer drug target, the anti-
proliferative effect of 1 and several derivatives was evaluated by
subjecting them to a panel of 39 types of cancer cells from various
origins developed at Japanese Foundation for Cancer Research
(Yamori, 2003). Based on HsDHODH inhibition by 1 and its
derivatives, the following compounds were selected for further
analysis; the three other most potent derivatives (7, 8, and 9),
including one which was more (12) and which is less (6) potent
than 1 (Table 4). We used the COMPARE algorithm (Kong and
Yamori, 2012) on a panel of human cancer cell lines to predict
the molecular targets or evaluate the mechanism of action of
test compounds through comparison of their growth inhibition
profiles to standard anti-cancer drugs and chemical tools with
known mechanism. The r-value obtained from COMPARE is
used to estimate the degree of similarity between the test and
standard compound pair. The r-value > 0.8 suggests similar
mechanism of action between two compounds. In the case of
1 and its derivatives, the highest r-value ranged from 0.557 to
0.619, thus showing that 1 and its derivatives have no similarity
to standard compounds tested and consequently indicate a
new mechanism of action. The three most potent HsDHODH
inhibitors (7, 8, and 9) tended to be more active while the least
active (12) was also less active against 39 cancer cells from the
panel (Table 4).
1 and Its Derivatives Potently Inhibit the
Viability of Human Cells Cultured Only
Under Hypoxia and Nutrient-Deprived
Conditions
Compound 10 (Table 2) is structurally related to 1 (Figure 1),
it is a potent inhibitor of complex III and the first reported
compound to bind at both Qo and Qi sites (Berry et al.,
2010). To investigate the possibility of complex III inhibition,
1 and its derivatives were assayed against succinate-cytochrome
c (complexes II–III) activity using bovine heart mitochondria
(Table 5). Compared to IC50 of 13 nM for compound 10 against
mammalian complex III (Berry et al., 2010), 1 and its derivatives
have much higher IC50s, i.e., in the micromolar range, except for
8 which gave an IC50 of 120 nM (Table 5). Several other inhibitors
of mitochondrial respiratory chain enzymes show preferential
cytotoxicity to human pancreatic cancer cells (Panc-1) under
hypoxia and nutrient-deprived conditions (Momose et al., 2010).
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TABLE 4 | Effect of 1 and its derivatives on 39 types of human cancer cells.
Origin Cell line GI50 (µM)
1 6 7 8 9 12
Br HBC-4 9.1 37.0 5.0 2.2 5.6 9.4
BSY-1 16.0 59.0 20.0 13.0 27.0 16.0
HBC-5 28.0 61.0 25.0 16.0 28.0 18.0
MCF-7 9.0 36.0 4.9 1.3 7.3 6.7
MDA-MB-231 7.4 36.0 11.0 2.8 14.0 10.0
CNS U251 1.5 5.1 1.5 0.43 0.97 4.9
SF-268 7.0 12.0 5.0 0.93 8.1 9.5
SF-295 5.3 16.0 8.0 1.3 11.0 16.0
SF-539 1.7 5.3 0.27 0.24 0.54 2.2
SNB-75 23.0 59.0 22.0 0.70 9.7 28.0
SNB-78 23.0 43.0 21.0 16.0 8.8 28.0
Co HCC2998 17.0 43.0 13.0 12.0 17.0 15.0
KM-12 9.3 32.0 5.7 2.0 6.4 10.0
HT-29 6.6 39.0 3.2 1.1 6.5 5.8
HCT-15 1.3 6.2 0.58 0.043 0.83 1.9
HCT-116 5.1 14.0 1.5 0.46 2.5 4.6
Lu NCI-H23 15.0 39.0 15.0 2.8 7.8 13.0
NCI-H226 15.0 24.0 11.0 10.0 13.0 8.0
NCI-H522 8.4 22.0 4.9 1.2 5.3 4.2
NCI-H460 2.0 12.0 0.94 0.21 4.3 4.5
A549 7.6 37.0 3.3 0.77 4.7 7.1
DMS273 5.9 18.0 0.91 0.45 3.0 3.6
DMS114 19.0 35.0 14.0 2.5 15.0 12.0
Me LOX-IMVI 2.8 13.0 1.5 0.61 2.1 3.4
Ov OVCAR-3 8.0 27.0 13.0 1.9 5.3 7.1
OVCAR-4 5.9 39.0 27.0 13.0 11.0 19.0
OVCAR-5 7.6 58.0 18.0 6.6 12.0 22.0
OVCAR-8 9.5 25.0 8.8 0.97 4.4 9.1
SK-OV-3 13.0 27.0 12.0 37.0 11.0 49.0
Re RXF-631L 12.0 45.0 7.5 11.0 8.4 16.0
ACHN 10.0 22.0 9.9 0.79 9.9 16.0
St St-4 14.0 44.0 13.0 1.1 7.5 17.0
MKN1 14.0 44.0 16.0 8.2 14.0 12.0
MKN7 15.0 36.0 16.0 2.1 13.0 16.0
MKN28 9.7 36.0 11.0 1.3 12.0 10.0
MKN45 10.0 65.0 20.0 6.4 14.0 24.0
MKN74 13.0 26.0 11.0 1.9 14.0 14.0
Pro DU-145 11.0 25.0 14.0 0.26 10.0 23.0
PC-3 13.0 22.0 15.0 1.2 22.0 13.0
The origin of cancer cell lines is as follows. Br, Breast; CNS, central nervous system; Co, colon; Lu, lung; Me, melanoma; Ov, ovary; Re, renal; St, stomach; Pro, prostate.
Concentrations of 1 and its derivatives causing 50% growth inhibition (GI50) between 10 and 1 µM are colored in yellow, between 1 and 0.1 µM are colored in red and
below 0.1 µM is colored in purple.
To investigate whether 1 also has similar effects, we measured
the viability of DLD-1 cells, which is derived from colon cancer
and known to growth under tumor microenvironment, after 1
treatment under normal cell culture conditions or under hypoxia
and nutrient-deprived conditions (Table 5). The viability of
cells cultured in the original medium under normal oxygen
concentration was approximately 80% even after exposure to
100 µM of 1 for 24 h (Figure 3, top panel). On the other hand,
1 showed remarkable reduction in the viability of cells cultured
under hypoxia and nutrient-deprived conditions (Figure 3, top
panel) with an IC50 value of 1.2 µM (Table 5).
Next, the effect in the viability of the three most potent
HsDHODH inhibitor 7, 8, and 9 was investigated. Similarly to
1, all three derivatives exhibited strong reduction in viability
specifically to the cells cultured under hypoxia and nutrient-
deprived culture conditions (Figure 3, top panel and Table 5).
Among the four compounds tested, 8 exhibited the most
potent reduction in DLD-1 viability with IC50 value 20-fold
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TABLE 5 | IC50 values of 1 and its derivatives on cultured cancerous (DLD-1) and non-cancerous (HDF) human cells at 24 or 48 h.
Compounds IC50 (µM)
DLD-1 (24 h) DLD-1 (48 h) HDF (24 h)
Normoxia nutrient (+) Hypoxia nutrient (−) Normoxia nutrient (+) Hypoxia nutrient (−) Normoxia nutrient (+) Hypoxia nutrient (−)
1 >100 1.2 ± 0.79 >100 0.24 ± 0.057 >100 1.5 ± 0.18
7 >100 2.0 ± 0.19 >100 0.95 ± 0.059 >100 3.4 ± 0.36
8 81 ± 24 0.066 ± 0.042 38 ± 3.3 0.024 ± 0.0030 61 ± 5.3 0.16 ± 0.023
9 >100 1.6 ± 0.42 >100 0.67 ± 0.066 >100 3.1 ± 0.19
IC50 values were analyzed and calculated by GraphPad PRISM 6 (GraphPad Co. Ltd., United States).
FIGURE 3 | Effects of 1 and its derivatives on survival of DLD-1 and HDF cells under normoxia/nutrient-rich conditions (circles) and hypoxia and nutrient-deprived
conditions (square). (Top panels) Survival rates of DLD-1 cells in presence of 1 and its derivatives for 24 h were measured using WST-8 assay. (Middle panels) Similar
experiment was performed, however, increasing the incubation time with HsDHODH inhibitors to 48 h. (Bottom panels) Same experiment as in top panels was
conducted using HDF cells. Each lane of panels, from left to right, shows the data obtained by incubation of indicated cells with 1, 7, 8, and 9, respectively. All data
represent the average from three independent experiments.
lower (0.066 µM) than 1 (1.2 µM) (Table 5). Lower cell
viability was also observed at a higher concentration of 8 under
normal culture conditions (Figure 3, top panel and Table 5).
Such a tendency was consistent with the result of the 39
cancer cell panel assay (Table 4). In all compounds tested,
the reduction in the viability was even more pronounced after
48 h treatment compared to 24 h treatment (Figure 3, middle
panel and Table 5). In order to evaluate the effect of 1 and its
derivatives on non-cancerous cells, the viability of HDF cells
after 24 h in the presence of compounds was also evaluated
under normal condition in addition to hypoxia and nutrient-
deprived conditions. As shown in Figure 3 (bottom panel) and
Table 5, the viability curve and the IC50s determined for all four
compounds against HDF were very similar to the results obtained
with DLD-1. Our results suggest that 1 and its derivatives are
selectively reducing the viability of human cells cultured under
hypoxia and nutrient-deprived conditions, regardless of cell
type.
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TABLE 6 | IC50 values of 1 and its derivatives on recombinant human DHODH and bovine complexes I–III, II–III, I, II, and III activities.
Compounds IC50 (µM) Inhibition (%)
HsDHODH Complexes I–III Complex II–III Complex I Complex II Complex III
1 0.038 ± 0.012 1.5 ± 0.04 13 ± 1.7 11 ± 5.8 1.5 ± 7.6 36 ± 1.2
7 0.0065 ± 0.0002 0.46 ± 0.01 2.3 ± 0.16 15 ± 2.3 3.2 ± 6.7 98 ± 4.4
8 0.006 ± 0.0005 0.048 ± 0.001 0.12 ± 0.013 43 ± 1.8 8.2 ± 4.9 87 ± 2.8
9 0.0042 ± 0.0004 1.0 ± 0.02 5.7 ± 0.37 7.6 ± 4.2 5.3 ± 4.1 87 ± 0.9
Rotenone >10 0.0063 ± 0.0001 >10 94 ± 1.5 6.4 ± 7.9 1.1 ± 2.8
Atpenin A5 >10 2.8 ± 0.44 0.0063 ± 0.0002 10 ± 2.7 97 ± 1.0 0.0 ± 4.6
10 2.3 ± 1.9 0.0033 ± 0.0001 0.0069 ± 0.0002 6.8 ± 4.1 3.6 ± 8.5 94 ± 2.4
The effect of each inhibitors on individual respiratory complexes were determined at 5 µM concentration. Rotenone (1 µM), atpenin A5 (0.1 µM), and ascochlorin (10,
1 µM) were used as positive control for inhibition of complexes I, II, and III activities, respectively. IC50 values were analyzed and calculated by GraphPad PRISM 6
(GraphPad Co. Ltd., United States).
At High Concentrations, 1 and Its
Derivatives Inhibit the Activity of
Respiratory Complex III
Since 1 and its derivatives inhibit HsDHODH by binding at the
ubiquinone binding site, the inhibitory effect of 1, 7, 8, and 9
against the mammalian respiratory complexes was investigated.
As shown in Table 6, the mammalian complexes I–III (NADH
cytochrome c reductase) activity was inhibited at micromolar
to low micromolar order, except for 8 which show IC50 of
48 nM. The complexes II–III (succinate cytochrome c reductase)
activity was also inhibited at slightly higher concentration than
the IC50 of complexes I–III (Table 6). Next, the inhibition
against individual respiratory complex activities were determined
(Table 6). At 5 µM concentration, 1, 7, and 9 were poor
inhibitors, while 8 inhibited 43% of complex I activity. None of
the inhibitors tested significantly inhibited the complex II activity
(Table 6). Finally, the ubiquinol oxidase activity of complex III
was inhibited by 7, 8, and 9. As positive control, rotenone, atpenin
A5, and ascochlorin (10) were used for complexes I, II, and
III, respectively (Table 6). Those results indicate that despite of
potent HsDHODH inhibition, those compounds start to inhibit
complex III activity at micromolar concentration.
DISCUSSION
In this study, we report on the first comprehensive SAR combined
with co-crystal structures of 1 and its derivatives on HsDHODH.
Interestingly, 1 was originally identified as having antitumor
and antiviral activities (Sasaki et al., 1973a,b). Recently, at
concentrations greater than 30 µM, 1 was reported to have
anti-inflammatory activity by suppressing the expression of
p-ERK1/2 and activation of NF-κB, AP-1(p-c-Jun) in RAW 264.7
macrophages (Park et al., 2017). At such high concentrations
of 1, not only is the activity of HsDHODH inhibited but
also that of complex III activity and thus, it is not clear
whether the anti-inflammatory response is the primary or
a secondary effect following inhibition of respiratory chain
enzymes. 1 and 10 are specific and potent inhibitors of
HsDHODH and complex III, respectively, and care must be
taken to interpret the biological data when using those two
compounds.
The SAR studies of 1 were clear and the results can be
summarized as follows: (i) the 1-aldehyde, 4-O−, 5-chlorine,
and 6-methyl group are essential for HsDHODH inhibitory
activity, (ii) the first isoprene unit from the linker is also
critical for enzyme inhibition, and (iii) the second isoprene unit
and the furanone ring are dispensable, however, depending on
the substitutions at terminal group, the inhibition activity can
increase. In our assay condition, the amount of purified enzyme
used was fixed at 10 nM. Considering that the IC50s of 7, 8, and
9 were being close to 5 nM, we can conclude that these three
derivatives bind to the HsDHODH at equimolar concentration
(i.e., 1:1 binding).
In order to evaluate the anti-cancer activity, a panel of 39
human cancer cells was assayed in the presence of 1 and its
derivatives. The results indicate that all HsDHODH inhibitors
tested had anti-cancer activity. Among the compounds tested,
compound 8 showed the strongest anti-cancer activity. This can
be related to the ability of compound 8 to inhibit complexes
I and III, in addition to HsDHODH, activities. Inhibition of
complex III in cancer cells can have pleiotropic effect, since
the electron flux from all other pathways, upstream of complex
III, would be suppressed. In addition to the 39 cancer cell
lines from the panel, we have also tested DLD-1 and non-
cancerous cell HDF cells. DLD-1 was chosen because it was
derived from colon cancer, which is known to growth under
tumor microenvironment. In addition, those two cell lines were
insensitive to high concentrations of 1 even after 48 h.
Tumor microenvironment is characterized by incomplete
vascularization, thus, resulting in low oxygenation (hypoxia)
and nutrient-deprived environment. The central regions of solid
tumors in microenvironments are exposed to limited oxygen and
nutrients because of vascular insufficiency (Brown and Giaccia,
1998). It was reported that even head and neck cancer, which
is surrounded by relatively higher concentrations of oxygen, is
exposed to only a quarter of normal oxygen tensions (Brown
and Wilson, 2004). However, some anti-cancer drugs for clinical
use, including 5-fluorouracil and bleomycin, show little cytotoxic
effects on cancer cells under hypoxia and nutrient-deprived
conditions (Teicher et al., 1981; Lu et al., 2004). In addition, they
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show low specificity for cancer cells, leading to severe side effects
(Khan et al., 2012). Since the supply of pyrimidine precursors
used for salvage pathway in the tumor microenvironment is
limited, the cells need to upregulate de novo biosynthesis to
meet the cellular pyrimidine demand. Accordingly, we have
hypothesized that under the tumor microenvironment cells
become highly dependent on the pyrimidine de novo pathways
and are also hypersensitive to HsDHODH inhibitors. Colorectal
cancer is such a kind of cells living under microenvironment
conditions and we chose DLD-1 because of its resistance to
1 when compared to other cancer cells from the panel. This
hypothesis is supported by the fact that 1 and the three most
potent derivatives showed selective and potent cytotoxicity to
DLD-1 cells under hypoxia and nutrient-deprived conditions.
Our result also suggests that cells under normal conditions
can survive using salvage pathway even in the presence of the
DHODH inhibitors.
The co-crystal structures reveal that 1 and its derivatives
inhibit HsDHODH by binding in the hydrophobic pocket formed
by the N-terminal extension specific for family 2 enzymes, which
we believed to be the ubiquinone-binding site. All substituents
from benzene ring were completely surrounded by amino acid
residues and interacting through hydrogen bonding, halogen
bonds, and hydrophobic interactions with distances less than 4 Å.
Co-crystal structures also revealed the hydrophobic interactions
formed by the first isoprene unit which we have shown to be
essential for inhibition. The interaction formed by the terminal
group varied between inhibitors and, in general, the terminal
group of the most potent inhibitors tended to exhibit more
interactions than weaker ones. Accordingly, the binding mode of
1 and its derivatives revealed by the co-crystal structures correlate
well with result obtained by our SAR study.
It has been reported that the activity of pyrimidine de novo
biosynthesis was suppressed by the inhibition of mitochondrial
complex III due to reduced turnover of ubiquinone necessary
for DHODH activity (Khutornenko et al., 2010). Therefore,
the rate of pyrimidine de novo biosynthesis in cells under
hypoxia is expected to decrease due to reduced electron flux
to dioxygen. In addition, it is likely that salvage pathways
are also affected under tumor microenvironment conditions
due to limited supply of pyrimidine precursors. Thus, it is
still unclear how cells living under microenvironments such as
solid tumors obtain pyrimidines to survive. We have previously
demonstrated that when DLD-1 cells are cultured under hypoxia
and nutrient-deprived conditions the Complexes III and IV
activities are repressed while fumarate reductase (FRD) activity
of mitochondrial complex II increases, which is the reverse
reaction of complex II, succinate–ubiquinone reductase (SQR)
(Tomitsuka et al., 2009). Under these conditions, the FRD
activity of complex II functions as a terminal quinol oxidase
(fumarate respiration) and facilitates the re-oxidation of NADH
by complex I (NADH-FRD system), the generation of an
electrochemical gradient and ATP synthesis (Tomitsuka et al.,
2010). The advantage of FRD activity is its ability to re-route
electron flux from respiratory quinone-dependent processes,
including HsDHODH, to fumarate when dioxygen availability
is low. The end-product of fumarate respiration is succinate,
which accumulates in the extracellular compartment. Such an
accumulation of succinate has been reported for cancer cells
cultured under hypoxia and in mouse models of ischemia
(Chouchani et al., 2014; Vazquez et al., 2016). We propose in
this paper that under hypoxia and nutrient-deprived conditions,
mitochondrial HsDHODH activity is connected to fumarate via
a low redox potential quinone (probably menaquinone) (Vos
et al., 2012) and complex II. In fact, this hypothesis is supported
by a previous report showing that DHODH is physically
associated with complex II in mitochondrial inner membrane
(Fang et al., 2012) which would be advantageous for efficient
electron flux from dihydroorotate to fumarate. In addition,
in cancer cells cultured under hypoxia and nutrient-deprived
conditions, Atpenin A5, which is a potent and specific complex
II inhibitor, showed the strongest cytotoxic effects compared to
other mitochondrial respiratory chain inhibitors (Momose et al.,
2010). In such circumstances where the oxygen uptake is already
limited, inhibition of fumarate respiration by Atpenin A5 must
have pleiotropic effect. Since 1 and its derivatives are ubiquinone
binding site inhibitors, enzymes from mammalian respiratory
chain that use ubiquinone or ubiquinol such as complexes I,
II, and III can potentially be inhibited. In order to verify this
hypothesis, bovine sub-mitochondrial particles were used and the
effect of 1, 7, 8, and 9 on complexes I–III, II–III, I, II, and III
activities was evaluated (Table 6). According to the biochemical
assays, those compounds at 5 µM concentration showed no or
little inhibition over complexes I and II while 7, 8, and 9 inhibited
the activity of complex III over 80%, which is consistent to the
observation where complexes I–III and II–III are also inhibited
(Table 6). The inhibition of complex III may become relevant
under normoxic condition where the electrons from ubiquinol
pool flow to dioxygen via complexes III and IV. Because the
activities of complexes III and IV are repressed or not functional
under hypoxic condition (Tomitsuka et al., 2009), inhibition of
complexes I or II rather than complex III can cause negative
impact to the viability of cells. This is also supported by the
potent growth inhibition activity of 8 under normoxia/nutrient-
rich and hypoxia/nutrient-deprived conditions. Taking together,
we can conclude that potent inhibition of cell viability specifically
under hypoxia/nutrient-deprived condition is caused due to (i)
inhibition of HsDHODH by 1, 7, and 9 and (ii) inhibition of both
of HsDHODH and complex I by 8. Under normoxia/nutrient-
rich condition, 1 and its derivatives may exert antiproliferative
effect due to additional inhibition of complex III. To the best
of our knowledge, this is the first report on the discovery of
HsDHODH equimolar binding inhibitors and evaluation of their
anticancer activity under tumor microenvironment-mimicking
condition.
We have also tested the effect of A771726, which is
an HsDHODH inhibitor (IC50 = 773 ± 78 nM) with
different scaffold used for treatment of RA, on DLD-1
under hypoxia/nutrient-deprived conditions. Because of
lower potency of A771726 against HsDHODH than 1 and
its derivatives, similar shift in the potency over DLD-1 was
expected. Consistently, similar pattern of specific inhibition
under hypoxia/nutrient-deprived condition was observed,
however, at higher concentrations (100 µM) of A771726
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(Supplementary Figure S7). Although this study strongly
suggest the potential to target HsDHODH in cancer cells living
under tumor microenvironment, future studies will explore
whether HsDHODH inhibitors with distinct scaffolds also exhibit
hypoxia-selective anticancer activity.
Another significant finding is that the hypersensitivity to
HsDHODH inhibitors was not limited to cancerous cells, as
similar result was also obtained with HDF cells. These results
indicate that under hypoxia and nutrient-deprived conditions,
cancerous and non-cancerous cells are highly dependent on
pyrimidine de novo biosynthesis. In addition, we have previously
found FRD activity in a variety of cancer cells and also in HDF
(Tomitsuka et al., 2009). At this point in time, it is tempting to
speculate that the ability to switch from oxygen respiration to
fumarate respiration in order to maintain the electrochemical
gradient and pyrimidine de novo biosynthesis through complex
I and DHODH, respectively, can be an important survival
response conserved in other human cells. Further study is needed
to elucidate the mitochondrial processes supported by FRD
activity from complex II under tumor microenvironment and
a chemogenomic validation of those pathways as drug target,
including HsDHODH.
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